Please assess the completion status of the following clinical trial:

Trial Title: CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory acute myeloid leukemia patients without severe complications such as active infections and bleedings; ECOG score less than 3.~Exclusion Criteria:~* Inablity to tolerate inducton chemotherapy; life expectancy less than 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CDIAG (Type: EXPERIMENTAL): Relapsed or refractroy acute myeloid leukemia patients reveive chidamide, decitabine combined with priming IAG regimen treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).